Tag: obligation

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

All amounts presented in this release are in U.S. Dollar (“USD”) unless otherwise stated.

DENVER and MIAMI, June 24, 2026 (GLOBE NEWSWIRE) -- The Western Union Company (“Western Union”) (NYSE: WU) and International Money Express, Inc. (“Intermex”) (NASDAQ: IMXI) today provided an update on the approval process and timeline for Western Union’s pending acquisition of Intermex. To date, money transmission regulators in 51 applicable U.S. states and territories and in all international jurisdictions have provided their approval of or non-objection to the acquisition, and approval or non-objection is currently pending from one U.S. state. Western Union and Intermex remain actively engaged in discussions with regulators, including the New York State Department of Financial Services, to obtain the final regulatory approval. Western Union and Intermex anticipate closing the transaction as soon as reasonably practicable upon receipt of such approval as well as satisfaction of other customary closing conditions.

TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2026 and events which occurred subsequent to year end. (All figures are in Canadian dollars unless otherwise stated)

GEORGE TOWN, Cayman Islands, June 24, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, today announced that its Cayman Islands retail water utility, Cayman Water Company Limited, has received a new license from the Utility Regulation and Competition Office of the Cayman Islands (“OfReg”) to provide potable water service to customers in its licensed service areas on Grand Cayman.

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).